Who Smokes? A Profile of Smokers in the US

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

ATLANTA-In 1995, an estimated 47 million adults in the United States were current smokers. A “Profile of Smokers” from the American Cancer Society’s Cancer Facts & Figures-1999 shows that, in that year, smoking prevalence was higher for men (27%) than women (22.6%) and highest among American Indians/Alaskan natives (36.2%), compared with other racial and ethnic groups.

ATLANTA—In 1995, an estimated 47 million adults in the United States were current smokers. A “Profile of Smokers” from the American Cancer Society’s Cancer Facts & Figures—1999 shows that, in that year, smoking prevalence was higher for men (27%) than women (22.6%) and highest among American Indians/Alaskan natives (36.2%), compared with other racial and ethnic groups.

Smoking prevalence was highest among men who had dropped out of school (41.9%). Among adult smokers, more than 80% started smoking by age 18, and more than half were already smoking regularly by that age.

In 1997, 36.4% of high school students were current cigarette smokers, ie, smoked at least one cigarette in the past 30 days.

Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Related Content